PRKCA
Protein kinase C alpha type
As of the edition of 20 October 2026, PRKCA (protein kinase C alpha type, UniProt P17252) has 2 drugs tested at it and 2 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P17252
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 6
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 5
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Isis 3521 | Went quiet | Phase 3 | none listed |
| Aprinocarsen | Went quiet | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Eli Lilly | Route A |
| Akcea Therapeutics | Route A |
The other 0 companies at PRKCA
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at PRKCA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.